Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Peroxiredoxin-1 Target Validation.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PRDX1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PRDX1 Recombinant Protein (Wild-Type & Active-Site Mutants) High purity (>95%), Endotoxin Controlled. Sequence Verified. Suitable for enzymatic and SPR binding assays. |
View PRDX1 Products |
| Gene Delivery | PRDX1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines to study ROS scavenging and chemoresistance. |
View PRDX1 Products |
| Benchmark Ab | Anti-PRDX1 Recombinant Antibody Recombinant positive control for Western Blot, IHC, and neutralization assays. |
View PRDX1 Products |
| Validator | PRDX1 siRNA Set For knockdown verification in target-engagement and phenotypic assays. |
View PRDX1 Products |
| Related Target A | PRDX2 Highly homologous family member. Crucial for selectivity counter-screening to avoid off-target toxicity. |
View PRDX2 Products |
| Related Target B | TLR4 Extracellular receptor for secreted PRDX1, mediating inflammatory signaling and metastasis. |
View TLR4 Products |
| Related Target C | TXN Thioredoxin, the physiological electron donor that reduces oxidized PRDX1. |
View TXN Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily Homology Counter-Screening (PRDX1 vs. PRDX2) | Highly purified, sequence-verified PRDX1 and PRDX2 recombinant proteins available for parallel selectivity profiling. |
| Mechanism of Action (Covalent Inhibitor Target Engagement) | Active-site mutant proteins (e.g., C52S, C173S) available to validate covalent binding specificity. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration. |
| False Positives | Validated siRNA sets included for target knockdown specificity checks. |
Live PRDX1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PRDX1 therapeutics is intensifying, with major players shifting focus from traditional antioxidant paradigms to targeted oncological and inflammatory interventions. As first-generation therapies reach the clinic, the next wave of R&D is targeting the dual role of PRDX1: intracellular ROS regulation in cancer survival and extracellular DAMP (Damage-Associated Molecular Pattern) signaling in metastasis.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutions, Biotech Startups | Solid Tumors (Breast, Lung, Pancreatic), Chemoresistance | Selectivity Assay (Need highly purified PRDX1 vs. PRDX2 proteins to prevent off-target toxicity) |
| Monoclonal Antibodies | Biopharma Innovators | Inflammatory Diseases, Cancer Metastasis | Neutralization Assay (Need high-purity extracellular PRDX1 and TLR4 binding partners) |
| siRNA / RNAi Therapeutics | RNA Therapeutics Specialists | Refractory Cancers | Knockdown Validation (Need validated siRNA sets and transfection-ready Lentivirus) |